These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2298705)

  • 61. Single case study. Complementary effects of phenelzine and psychotherapy in long term treatment of depression.
    Davidson J; Raft D; Freeman C
    J Nerv Ment Dis; 1979 Oct; 167(10):632-4. PubMed ID: 114605
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Relationship of platelet MAO activity to characteristics of major depressive illness.
    Georgotas A; McCue RE; Friedman E; Hapworth WE; Kim OM; Cooper TB; Chang I; Stokes PE
    Psychiatry Res; 1986 Dec; 19(4):247-56. PubMed ID: 3809323
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How effective and safe is continuation therapy in elderly depressed patients? Factors affecting relapse rate.
    Georgotas A; McCue RE; Cooper TB; Nagachandran N; Chang I
    Arch Gen Psychiatry; 1988 Oct; 45(10):929-32. PubMed ID: 3421805
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phenelzine in depressed patients. Effects on urinary MHPG excretion in relation to clinical response.
    Beckmann H; Murphy DL
    Neuropsychobiology; 1977; 3(1):49-55. PubMed ID: 895998
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Platelet MAO-B and endogenous MAO-A inhibitory activity in depressed patients: stability with electroconvulsive treatment.
    Moriearty PL; Herrick C; Shafey M; Bornstein P; Becker RE
    Biol Psychiatry; 1987 Sep; 22(9):1155-8. PubMed ID: 3651533
    [No Abstract]   [Full Text] [Related]  

  • 66. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design.
    Quitkin FM; Harrison W; Stewart JW; McGrath PJ; Tricamo E; Ocepek-Welikson K; Rabkin JG; Wager SG; Nunes E; Klein DF
    Arch Gen Psychiatry; 1991 Apr; 48(4):319-23. PubMed ID: 2009033
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Platelet markers of suicidality.
    Meltzer HY; Arora RC
    Ann N Y Acad Sci; 1986; 487():271-80. PubMed ID: 3471162
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Use of phenelzine in continuation therapy.
    Davidson J; Raft D
    Neuropsychobiology; 1984; 11(3):191-4. PubMed ID: 6433222
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pain as a symptom in depressive disorders and its relationship to platelet monoamine oxidase activity.
    von Knorring L; Perris C; Oreland L; Eisemann M; Eriksson U; Perris H
    J Neural Transm; 1984; 60(1):1-9. PubMed ID: 6207267
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mania associated with high percentage of inhibition of monoamine oxidase.
    Bowden CL; Seleshi E; Javors MA
    Am J Psychiatry; 1989 Jan; 146(1):121. PubMed ID: 2912232
    [No Abstract]   [Full Text] [Related]  

  • 71. The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine.
    Johnstone EC
    Psychopharmacologia; 1976 Apr; 46(3):289-94. PubMed ID: 951464
    [TBL] [Abstract][Full Text] [Related]  

  • 72. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.
    Mendlewicz J; Youdim MB
    Br J Psychiatry; 1983 May; 142():508-11. PubMed ID: 6409196
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Changes in MAO activity during estrogen treatment of females with endogenous depression.
    Holsboer F; Benkert O; Demisch L
    Mod Probl Pharmacopsychiatry; 1983; 19():321-6. PubMed ID: 6865971
    [No Abstract]   [Full Text] [Related]  

  • 74. Platelet MAO in functional psychoses with evidence of brain atrophy.
    Luchins DJ; Arora RC; Meltzer HY
    Am J Psychiatry; 1985 Aug; 142(8):996-7. PubMed ID: 4025609
    [No Abstract]   [Full Text] [Related]  

  • 75. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression.
    Davidson J; McLeod M; Law-Yone B; Linnoila M
    Arch Gen Psychiatry; 1978 May; 35(5):639-42. PubMed ID: 727903
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients.
    Georgotas A; McCue RE; Cooper TB
    Arch Gen Psychiatry; 1989 Sep; 46(9):783-6. PubMed ID: 2673129
    [TBL] [Abstract][Full Text] [Related]  

  • 77. What is the clinical significance of an elevated platelet MAO level?
    Pies RW
    J Clin Psychopharmacol; 1996 Dec; 16(6):472-3. PubMed ID: 8959484
    [No Abstract]   [Full Text] [Related]  

  • 78. Platelet MAO activity in clinical subtypes of depression and DST suppression.
    Poirier MF; Lôo H; Mitrani N; Benkelfat C; Askienazy S; Le Fur G
    Acta Psychiatr Scand; 1987 May; 75(5):456-63. PubMed ID: 3604729
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Abuse of monoamine oxidase inhibitors.
    Baumbacher G; Hansen MS
    Am J Drug Alcohol Abuse; 1992; 18(4):399-406. PubMed ID: 1449122
    [TBL] [Abstract][Full Text] [Related]  

  • 80. 'Pseudo-allergy': treatment with an MAO inhibitor.
    Ulwelling W
    Psychosomatics; 1985 Jun; 26(6):535-6. PubMed ID: 4011820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.